Wide Ranks

ASRT

Assertio Holdings, Inc.

0.9775

Top Statistics
Market Cap 93 M Forward PE 6.24 Revenue Growth -18.00 %
Current Ratio 2.01 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -54.46 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 4.20 Enterprise / Revenue 0.3440 Price To Sales Trailing12 Months 0.7421
Profitability
Profit Margins -54.46 % Operating Margins -9.41 %
Balance Sheet
Total Cash 88 M Total Cash Per Share 0.9360 Total Debt 39 M
Total Debt To Equity 30.14 Current Ratio 2.01 Book Value Per Share 1.38
All Measures
Short Ratio 820.00 % Message Board Id finmb_363049 Fax 510 744 8001
Shares Short Prior Month 6 M Return On Equity -0.4236 City Lake Forest
Uuid b0b71d5e-e500-3f56-bb27-7703d923929a Previous Close 0.9790 First Trade Date Epoch Utc 881 M
Book Value 1.38 Beta 0.8350 Total Debt 39 M
Volume 225711 Price To Book 0.7088 Last Split Date 1 B
Fifty Two Week Low 0.7300 Total Cash Per Share 0.9360 Total Revenue 125 M
Shares Short Previous Month Date 1 B Target Median Price 3.00 Audit Risk 5
Max Age 86400 Recommendation Mean 1.50 Sand P52 Week Change 0.3133
Operating Margins -9.41 % Target Mean Price 3.03 Net Income To Common -68489000
Short Percent Of Float 0.0662 Implied Shares Outstanding 95 M Trailing Peg Ratio 122.19 %
Last Fiscal Year End 1 B Average Daily Volume10 Day 751760 Average Volume10days 751760
Total Cash 88 M Next Fiscal Year End 1 B Revenue Per Share 1.32
Held Percent Insiders 0.0262 Ebitda Margins 8.20 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 1
Regular Market Previous Close 0.9790 Target Low Price 2.15 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.06 Open 0.9800 Free Cashflow 12 M
State IL Dividend Yield 0.00 % Return On Assets -0.0261
Time Zone Short Name EST Board Risk 4 Trailing Eps -0.4400
Day Low 0.9703 Address1 100 South Saunders Road Shares Outstanding 95 M
Compensation Risk 8 Price Hint 4 Target High Price 4.00
Website https://www.assertiotx.com 52 Week Change -0.0392 Average Volume 598403
Forward Eps -0.0600 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 148.20 % Last Split Factor 1:4 Regular Market Day High 1.00
Is_sp_500 False Profit Margins -54.46 % Debt To Equity 30.14
Fifty Two Week High 1.80 Day High 1.00 Shares Short 6 M
Regular Market Open 0.9800 Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 %
Enterprise To Revenue 0.3440 Revenue Growth -18.00 % Shares Percent Shares Out 0.0655
Operating Cashflow 20 M Currency USD Time Zone Full Name America/New_York
Market Cap 93 M Is_nasdaq_100 False Zip 60045
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name Assertio Holdings, Inc.
Overall Risk 3 Regular Market Day Low 0.9703 Held Percent Institutions 0.3195
Current Price 0.9775 Address2 Suite 300 Enterprise To Ebitda 4.20
Financial Currency USD Current Ratio 2.01 Gross Margins 72.22 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 5 Country United States
Float Shares 83 M Two Hundred Day Average 1.10 Governance Epoch Date 1 B
Enterprise Value 43 M Price To Sales Trailing12 Months 0.7421 Forward PE 6.24
Regular Market Volume 225711 Ebitda 10 M Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States.

Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.

It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia.

The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.

Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.